Letters, Testimony & Comments

September 6, 2005
Comments by BIO; CMS-1325-IFC (Medicare Program; Competative Acquisition of Outpatient Drugs and Biologicals Under Part B)
August 8, 2005
Comments by BIO; FDA Draft guidance; Docket 0062, Federal Register: May 10, 2005 (Volume 70, No. 89)
July 26, 2005
The letter, signed by over 280 biotech executives, emphasizes support for restoring eligibility in the SBIR program to venture-backed bioscience companies.
July 13, 2005
Comments by BIO; FDA Docket 2005D-0122
June 15, 2005
Thanks to Speaker Tom Finneran and to Massachusetts Biotechnology Council for the opportunity to be with you today. Mr. Speaker, I seek unanimous consent to address the house. I'm from Bucks County, Pennsylvania - just outside of...
May 11, 2005
Dear Governor Murkowski: On behalf of the Biotechnology Industry Organization (BIO), we would like to express concern about a bill before you: Senate Bill 25, “An Act relating to labeling and identification of genetically modified fish...
April 29, 2005
Testimony of the Biotechnology Industry Organization Submitted to the California Assembly Committee on Agriculture April 29, 2005 Regarding Assembly Bill 984: Manufacturer Liability On behalf of the members of the Biotechnology Industry...
April 29, 2005
Testimony to the California Assembly Committee on Agriculture regarding Assembly Bill 984: Manufacturer Liability
April 26, 2005
Docket No. 2005D-0004, Federal Register: January 26th, 2005 (Volume 70, Pages 3714-3715).
April 11, 2005
Testimony of the Biotechnology Industry Organization (BIO) Before the Texas House of Representatives State Affairs Committee Regarding House Bill 1929 The Use of Human Cells and Tissue Thank you for the opportunity to present testimony today in...
April 11, 2005
Testimony of the Biotechnology Industry Organization (BIO) before the Texas House of Representatives State Affairs Committee, regarding House Bill 1929: The Use of Human Cells and Tissue. (April 11, 2005)
April 8, 2005
Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act
April 7, 2005
Squaring our Shoulders Against Neglected Diseases: Advanced Purchase Commitment Plan an Important Step
March 27, 2005
The Biotechnology Industry Organization (“BIO”) is pleased to have the opportunity to comment on the Food and Drug Administration’s (“FDA’s” or the “agency’s”) draft guidance on using a...